Cargando…

A SGLT2 inhibitor dapagliflozin suppresses prolonged ventricular-repolarization through augmentation of mitochondrial function in insulin-resistant metabolic syndrome rats

BACKGROUND: Metabolic syndrome (MetS) is a prevalent risk factor for cardiac dysfunction. Although SGLT2-inhibitors have important cardioprotective effects in hyperglycemia, their underlying mechanisms are complex and not completely understood. Therefore, we examined mechanisms of a SGLT2-inhibitor...

Descripción completa

Detalles Bibliográficos
Autores principales: Durak, Aysegul, Olgar, Yusuf, Degirmenci, Sinan, Akkus, Erman, Tuncay, Erkan, Turan, Belma
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6240275/
https://www.ncbi.nlm.nih.gov/pubmed/30447687
http://dx.doi.org/10.1186/s12933-018-0790-0
_version_ 1783371611769929728
author Durak, Aysegul
Olgar, Yusuf
Degirmenci, Sinan
Akkus, Erman
Tuncay, Erkan
Turan, Belma
author_facet Durak, Aysegul
Olgar, Yusuf
Degirmenci, Sinan
Akkus, Erman
Tuncay, Erkan
Turan, Belma
author_sort Durak, Aysegul
collection PubMed
description BACKGROUND: Metabolic syndrome (MetS) is a prevalent risk factor for cardiac dysfunction. Although SGLT2-inhibitors have important cardioprotective effects in hyperglycemia, their underlying mechanisms are complex and not completely understood. Therefore, we examined mechanisms of a SGLT2-inhibitor dapagliflozin (DAPA)-related cardioprotection in overweight insulin-resistant MetS-rats comparison with insulin (INSU), behind its glucose-lowering effect. METHODS: A 28-week high-carbohydrate diet-induced MetS-rats received DAPA (5 mg/kg), INSU (0.15 mg/kg) or vehicle for 2 weeks. To validate MetS-induction, we monitored all animals weekly by measuring body weight, blood glucose and HOMO-IR index, electrocardiograms, heart rate, systolic and diastolic pressures. RESULTS: DAPA-treatment of MetS-rats significantly augmented the increased blood pressure, prolonged Q–R interval, and low heart rate with depressed left ventricular function and relaxation of the aorta. Prolonged-action potentials were preserved with DAPA-treatment, more prominently than INSU-treatment, at most, through the augmentation in depressed voltage-gated K(+)-channel currents. DAPA, more prominently than INSU-treatment, preserved the depolarized mitochondrial membrane potential, and altered mitochondrial protein levels such as Mfn-1, Mfn-2, and Fis-1 as well as provided significant augmentation in cytosolic Ca(2+)-homeostasis. Furthermore, DAPA also induced significant augmentation in voltage-gated Na(+)-currents and intracellular pH, and the cellular levels of increased oxidative stress, protein-thiol oxidation and ADP/ATP ratio in cardiomyocytes from MetS rats. Moreover, DAPA-treatment normalized the increases in the mRNA level of SGLT2 in MetS-rat heart. CONCLUSIONS: Overall, our data provided a new insight into DAPA-associated cardioprotection in MetS rats, including suppression of prolonged ventricular-repolarization through augmentation of mitochondrial function and oxidative stress followed by improvement of fusion–fission proteins, out of its glucose-lowering effect. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12933-018-0790-0) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-6240275
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-62402752018-11-23 A SGLT2 inhibitor dapagliflozin suppresses prolonged ventricular-repolarization through augmentation of mitochondrial function in insulin-resistant metabolic syndrome rats Durak, Aysegul Olgar, Yusuf Degirmenci, Sinan Akkus, Erman Tuncay, Erkan Turan, Belma Cardiovasc Diabetol Original Investigation BACKGROUND: Metabolic syndrome (MetS) is a prevalent risk factor for cardiac dysfunction. Although SGLT2-inhibitors have important cardioprotective effects in hyperglycemia, their underlying mechanisms are complex and not completely understood. Therefore, we examined mechanisms of a SGLT2-inhibitor dapagliflozin (DAPA)-related cardioprotection in overweight insulin-resistant MetS-rats comparison with insulin (INSU), behind its glucose-lowering effect. METHODS: A 28-week high-carbohydrate diet-induced MetS-rats received DAPA (5 mg/kg), INSU (0.15 mg/kg) or vehicle for 2 weeks. To validate MetS-induction, we monitored all animals weekly by measuring body weight, blood glucose and HOMO-IR index, electrocardiograms, heart rate, systolic and diastolic pressures. RESULTS: DAPA-treatment of MetS-rats significantly augmented the increased blood pressure, prolonged Q–R interval, and low heart rate with depressed left ventricular function and relaxation of the aorta. Prolonged-action potentials were preserved with DAPA-treatment, more prominently than INSU-treatment, at most, through the augmentation in depressed voltage-gated K(+)-channel currents. DAPA, more prominently than INSU-treatment, preserved the depolarized mitochondrial membrane potential, and altered mitochondrial protein levels such as Mfn-1, Mfn-2, and Fis-1 as well as provided significant augmentation in cytosolic Ca(2+)-homeostasis. Furthermore, DAPA also induced significant augmentation in voltage-gated Na(+)-currents and intracellular pH, and the cellular levels of increased oxidative stress, protein-thiol oxidation and ADP/ATP ratio in cardiomyocytes from MetS rats. Moreover, DAPA-treatment normalized the increases in the mRNA level of SGLT2 in MetS-rat heart. CONCLUSIONS: Overall, our data provided a new insight into DAPA-associated cardioprotection in MetS rats, including suppression of prolonged ventricular-repolarization through augmentation of mitochondrial function and oxidative stress followed by improvement of fusion–fission proteins, out of its glucose-lowering effect. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12933-018-0790-0) contains supplementary material, which is available to authorized users. BioMed Central 2018-11-17 /pmc/articles/PMC6240275/ /pubmed/30447687 http://dx.doi.org/10.1186/s12933-018-0790-0 Text en © The Author(s) 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Original Investigation
Durak, Aysegul
Olgar, Yusuf
Degirmenci, Sinan
Akkus, Erman
Tuncay, Erkan
Turan, Belma
A SGLT2 inhibitor dapagliflozin suppresses prolonged ventricular-repolarization through augmentation of mitochondrial function in insulin-resistant metabolic syndrome rats
title A SGLT2 inhibitor dapagliflozin suppresses prolonged ventricular-repolarization through augmentation of mitochondrial function in insulin-resistant metabolic syndrome rats
title_full A SGLT2 inhibitor dapagliflozin suppresses prolonged ventricular-repolarization through augmentation of mitochondrial function in insulin-resistant metabolic syndrome rats
title_fullStr A SGLT2 inhibitor dapagliflozin suppresses prolonged ventricular-repolarization through augmentation of mitochondrial function in insulin-resistant metabolic syndrome rats
title_full_unstemmed A SGLT2 inhibitor dapagliflozin suppresses prolonged ventricular-repolarization through augmentation of mitochondrial function in insulin-resistant metabolic syndrome rats
title_short A SGLT2 inhibitor dapagliflozin suppresses prolonged ventricular-repolarization through augmentation of mitochondrial function in insulin-resistant metabolic syndrome rats
title_sort sglt2 inhibitor dapagliflozin suppresses prolonged ventricular-repolarization through augmentation of mitochondrial function in insulin-resistant metabolic syndrome rats
topic Original Investigation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6240275/
https://www.ncbi.nlm.nih.gov/pubmed/30447687
http://dx.doi.org/10.1186/s12933-018-0790-0
work_keys_str_mv AT durakaysegul asglt2inhibitordapagliflozinsuppressesprolongedventricularrepolarizationthroughaugmentationofmitochondrialfunctionininsulinresistantmetabolicsyndromerats
AT olgaryusuf asglt2inhibitordapagliflozinsuppressesprolongedventricularrepolarizationthroughaugmentationofmitochondrialfunctionininsulinresistantmetabolicsyndromerats
AT degirmencisinan asglt2inhibitordapagliflozinsuppressesprolongedventricularrepolarizationthroughaugmentationofmitochondrialfunctionininsulinresistantmetabolicsyndromerats
AT akkuserman asglt2inhibitordapagliflozinsuppressesprolongedventricularrepolarizationthroughaugmentationofmitochondrialfunctionininsulinresistantmetabolicsyndromerats
AT tuncayerkan asglt2inhibitordapagliflozinsuppressesprolongedventricularrepolarizationthroughaugmentationofmitochondrialfunctionininsulinresistantmetabolicsyndromerats
AT turanbelma asglt2inhibitordapagliflozinsuppressesprolongedventricularrepolarizationthroughaugmentationofmitochondrialfunctionininsulinresistantmetabolicsyndromerats
AT durakaysegul sglt2inhibitordapagliflozinsuppressesprolongedventricularrepolarizationthroughaugmentationofmitochondrialfunctionininsulinresistantmetabolicsyndromerats
AT olgaryusuf sglt2inhibitordapagliflozinsuppressesprolongedventricularrepolarizationthroughaugmentationofmitochondrialfunctionininsulinresistantmetabolicsyndromerats
AT degirmencisinan sglt2inhibitordapagliflozinsuppressesprolongedventricularrepolarizationthroughaugmentationofmitochondrialfunctionininsulinresistantmetabolicsyndromerats
AT akkuserman sglt2inhibitordapagliflozinsuppressesprolongedventricularrepolarizationthroughaugmentationofmitochondrialfunctionininsulinresistantmetabolicsyndromerats
AT tuncayerkan sglt2inhibitordapagliflozinsuppressesprolongedventricularrepolarizationthroughaugmentationofmitochondrialfunctionininsulinresistantmetabolicsyndromerats
AT turanbelma sglt2inhibitordapagliflozinsuppressesprolongedventricularrepolarizationthroughaugmentationofmitochondrialfunctionininsulinresistantmetabolicsyndromerats